11/09/2020 8:54 AM
Clarín.com
World
Updated 11/09/2020 9:03 AM
Pharmaceutical Pfizer said Monday that its coronavirus vaccine is "90% effective," according to the first interim analysis of its phase 3 trial, the last stage before formally requesting approval.
This protective efficacy against the SARS-CoV-2 virus was achieved seven days after the second dose of the vaccine and 28 days after the first, the US pharmaceutical company indicated in a joint statement with BioNTech.
The data is more than optimistic since scientists expect an effectiveness of around 75%.
Albert Bourla, president and CEO of Pfizer, hailed the development as a "great day for science and humanity."
The analysis evaluated 94 confirmed Covid-19 infections among 43,538 trial participants.
Pfizer and BioNTech stated that the division of cases between vaccinated people and those who received a placebo indicated a vaccine efficacy rate greater than 90% seven days after the second dose.
"Efficacy in the majority of participants, safety data, and consistent manufacturing are the three requirements that are needed before you can apply for emergency use authorization," the pharmacist said.
News in development.
JPE